QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Sponsor

ImmunityBio, Inc. (Industry)

Overall Status

Unknown status

CT.gov ID

NCT03136406

Collaborator

(none)

Enrollment

Location

Arm

43.6

Anticipated Duration (Months)

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous Standard of Care first line therapy and chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Pancreatic Cancer	Drug: Cyclophosphamide Drug: Oxaliplatin Drug: Capecitabine Drug: 5-Fluorouracil Drug: Leucovorin Drug: nab-paclitaxel Biological: bevacizumab Biological: avelumab Biological: ALT-803 Biological: aNK for Infusion Biological: ETBX-011 Biological: GI-4000	Phase 1/Phase 2

Detailed Description

Treatment will be administered in two phases. Subjects will continue treatment until they experience progressive disease (PD) or experience unacceptable toxicity (not correctable with dose reduction), withdraw consent, or the investigator feels it is no longer in the subject's best interest to continue treatment. Those who have a complete response (CR) will enter phase 2 of the study. Subjects may remain on phase 2 of the study for up to 1 year. Treatment will continue throughout phase 2 until the subject experiences PD or unacceptable toxicity, withdraws consent, or the investigator feels it is no longer in the subject's best interest to continue treatment.

Study Design

Study Type:

Interventional

Actual Enrollment :

3 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

Actual Study Start Date :

Aug 14, 2017

Anticipated Primary Completion Date :

Dec 1, 2020

Anticipated Study Completion Date :

Apr 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: NANT Pancreatic Cancer Vaccine A combination of agents will be administered to subjects in this study: cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011.	Drug: Cyclophosphamide 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate Drug: Oxaliplatin cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum Drug: Capecitabine 5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine Drug: 5-Fluorouracil 5-fluoro-2,4 (1H,3H)-pyrimidinedione Drug: Leucovorin L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt Drug: nab-paclitaxel Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin Biological: bevacizumab Recombinant human anti-VEGF IgG1 monoclonal Biological: avelumab Recombinant human anti-PD-L1 IgG1 monoclonal antibody Biological: ALT-803 Recombinant human super agonist interleukin-15 (IL-15) complex Biological: aNK for Infusion NK-92 cells Biological: ETBX-011 Ad5 [E1-, E2b-]-CEA Biological: GI-4000 Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

Arm

Intervention/Treatment

Experimental: NANT Pancreatic Cancer Vaccine

A combination of agents will be administered to subjects in this study: cyclophosphamide, oxaliplatin, capecitabine, fluorouracil, leucovorin, nab-paclitaxel, bevacizumab, avelumab, ALT-803, aNK, GI-4000, and ETBX-011.

Drug: Cyclophosphamide

2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Drug: Oxaliplatin

cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum

Drug: Capecitabine

5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine

Drug: 5-Fluorouracil

5-fluoro-2,4 (1H,3H)-pyrimidinedione

Drug: Leucovorin

L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt

Drug: nab-paclitaxel

Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Biological: bevacizumab

Recombinant human anti-VEGF IgG1 monoclonal

Biological: avelumab

Recombinant human anti-PD-L1 IgG1 monoclonal antibody

Biological: ALT-803

Recombinant human super agonist interleukin-15 (IL-15) complex

Biological: aNK for Infusion

NK-92 cells

Biological: ETBX-011

Ad5 [E1-, E2b-]-CEA

Biological: GI-4000

Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

Outcome Measures

Primary Outcome Measures

Incidence of treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs), graded using the NCI CTCAE Version 4.03. [8 weeks]
Phase 1b primary endpoint
Objective response rate by RECIST [1 year]
Phase 2 primary endpoint
Objective response rate by irRC [1 year]
Phase 2 primary endpoint

Secondary Outcome Measures

Objective response rate by RECIST [8 weeks]
Phase 1b secondary endpoint
Objective response rate by irRC [8 weeks]
Phase 1b secondary endpoint
Progression-free survival by RECIST during Phase 1b [8 weeks]
Phase 1b secondary endpoint
Progression-free survival by irRC during Phase 1b [8 weeks]
Phase 1b secondary endpoint
Overall survival [8 weeks]
Phase 1b secondary endpoint
Patient-reported outcomes of pancreatic cancer symptoms [8 weeks]
Phase 1b secondary endpoint
Progression-free survival by RECIST during Phase 2 [1 year]
Phase 2 secondary endpoint
Progression-free survival by irRC during Phase 2 [1 year]
Phase 2 secondary endpoint
Overall survival [1 year]
Phase 2 secondary endpoint
Duration of response [1 year]
Phase 2 secondary endpoint
Disease control rate (confirmed complete response, partial response, or stable disease lasting for at least 2 months). [1 year]
Phase 2 secondary endpoint
Patient-reported outcomes of pancreatic cancer symptoms [1 year]
Phase 2 secondary endpoint
Incidence of treatment-emergent AEs, SAEs, graded using the NCI CTCAE Version 4.03. [1 year]
Phase 2 secondary endpoint

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Age ≥ 18 years old.
Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines.
Histologically-confirmed pancreatic cancer with progression on or after SoC therapy.
ECOG performance status of 0 to 2.
Have at least 1 measurable lesion and/or non-measurable disease evaluable according to RECIST Version 1.1.
Must have a recent tumor biopsy specimen following the conclusion of the most recent anti-cancer treatment. If a historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period.
Must be willing to provide blood samples for exploratory analyses.
Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
Agreement to practice effective contraception for female subjects with child-bearing potential and non-sterile males.

Exclusion Criteria:

History of persistent grade 2 or higher (CTCAE Version 4.03) hematological toxicity resulting from previous therapy.
History of other active malignancies or brain metastasis except: controlled basal cell carcinoma; prior history of in situ cancer (eg, breast, melanoma, cervical); prior history of prostate cancer that is not under active systemic treatment (except hormonal therapy) and with undetectable prostate-specific antigen (PSA) (< 0.2 ng/mL); bulky (≥ 1.5 cm) disease with metastasis in the central hilar area of the chest and involving the pulmonary vasculature. Subjects with a history of another malignancy must have > 5 years without evidence of disease.
Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment-related complications.
Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma).
History of organ transplant requiring immunosuppression.
History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
Requires whole blood transfusion to meet eligibility criteria.
Inadequate organ function, evidenced by the following laboratory results:
White blood cell (WBC) count < 3,500 cells/mm3
Absolute neutrophil count < 1,500 cells/mm3.
Platelet count < 100,000 cells/mm3.
Hemoglobin < 9 g/dL.
Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).
Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT])

2.5 × ULN (> 5 × ULN in subjects with liver metastases).

Alkaline phosphatase levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
Serum creatinine > 2.0 mg/dL or 177 μmol/L.
International normalized ratio (INR) or activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) >1.5 × ULN (unless on therapeutic anti-coagulation).
Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication.
Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.
Positive results of screening test for human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV).
Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
Known hypersensitivity to any component of the study medication(s).
Subjects taking any medication(s) (herbal or prescribed) known to have an adverse drug reaction with any of the study medications. See Excluded Medications list.
Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to screening for this study, except for testosterone-lowering therapy in men with prostate cancer.
Assessed by the investigator to be unable or unwilling to comply with the requirements of the protocol.
Concurrent participation in any interventional clinical trial.
Pregnant and nursing women.